Recent Posts
- Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology
- Dyadic Announces Third Quarter 2024 Financial Results and Strategic Progress Across Key Markets
- Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
- Dyadic Expands Global Presence with Participation in Key Industry Events
- Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference
Recent Comments
No comments to show.